First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies

被引：7

作者：

Krebs, M. G. ^{[1
]}

Lord, S. ^{[2
]}

Kenny, L. ^{[3
]}

Baird, R. D. ^{[4
]}

MacPherson, I. ^{[5
]}

Bahl, A. ^{[6
]}

Clack, G. ^{[7
]}

Ainscow, E. ^{[8
]}

Barrett, A. G. ^{[9
]}

Dickinson, P. ^{[10
]}

Fuchter, M. J. ^{[9
]}

Lehnert, M. ^{[11
]}

Ali, S. ^{[12
]}

Mcintosh, S. ^{[7
]}

Coombes, R. C. ^{[13
]}

机构：

[1] Christie NHS Fdn Trust, Expt Canc Med Team, Manchester, Lancs, England

[2] Univ Oxford, Churchill Hosp, Oxford, England

[3] Charing Cross Hosp, Imperial Coll Healthcare NHS Trust, Clin Res, London, England

[4] Cambridge Univ Hosp NHS Fdn Trust, Oncol, Addenbrookes Hosp, Cambridge, Cambridgeshire, England

[5] NHS Greater Glasgow & Clyde, Beatson West Scotland Canc Ctr, BWSCC, Med Oncol Dept, Glasgow, Lanark, Scotland

[6] Preclin Res, Carrick Therapeut, Dublin, Ireland

[7] Carrick Therapeut, Clin Res, Dublin, Ireland

[8] Carrick Therapeut, Discovery, Dublin, Ireland

[9] Charing Cross Hosp, Chem, Imperial Coll Healthcare NHS Trust, London, England

[10] SEDA PDS, Clin Res, Macclesfield, Cheshire, England

[11] Carrick Therapeut, Clin Res, Dublin, Ireland

[12] Charing Cross Hosp, Imperial Coll Healthcare NHS Trust, Surg & Canc, London, England

[13] Hammersmith Hosp, Imperial Coll London, Clin Res, London, England

来源：

关键词：

D O I：

10.1016/j.annonc.2021.08.513

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

230MO

引用

页码：S458 / S458

页数：1